Study: State Laws Shape Peptide Access in Sexual Medicine

Where you live may matter just as much as what your doctor prescribes. A peer-reviewed study published in Sexual Medicine in July 2026 suggests that access to peptide-based therapies in sexual medicine is not solely determined by federal regulatory status — but is significantly shaped by the patchwork of state-level healthcare policies governing telehealth, nursing practice authority, and pharmaceutical compounding infrastructure. The findings raise important questions about health equity and the practical realities patients and clinicians face when navigating this evolving therapeutic landscape (Quesada et al., 2026).

What This Study Found

Researchers conducted a cross-sectional analysis of all 50 U.S. states and the District of Columbia, examining three key proxy variables that reflect the real-world clinical feasibility of accessing peptide-based sexual medicine therapies:

1. Telehealth prescribing permissiveness — the degree to which state law allows clinicians to initiate and manage care remotely
2. Nurse practitioner (NP) practice authority — whether NPs can evaluate and prescribe independently or require physician oversight
3. Availability of FDA-registered 503B outsourcing facilities — the presence of regulated compounding pharmacies capable of producing peptide therapies at scale, normalized by population

These three variables were combined into a composite Peptide Access Environment Score (PAES), which allowed the research team to rank and stratify states into high-, moderate-, and low-access tiers.

The results revealed substantial interstate variability. PAES values ranged from a low of 0.33 to a high of 1.56 — a nearly fivefold difference. High-access environments clustered predominantly in the Northeast and West, while low-access states were most frequently observed in the South and parts of the Midwest. Regional differences were statistically significant (p < .001).

Perhaps most striking was a pattern of discordance identified between telehealth permissiveness and compounding infrastructure. Researchers found that multiple states permit telehealth initiation of care — meaning a patient can legally consult with a provider remotely — yet lack sufficient in-state 503B compounding facilities to fulfill a prescription. Conversely, other states possess robust compounding capacity but maintain restrictive telehealth regulations that limit a patient's ability to even initiate care with a qualified provider. The study suggests this structural mismatch may create access gaps that are invisible to both patients and policymakers.

Clinical Significance

For clinicians practicing in sexual medicine, these findings carry meaningful implications. The study suggests that a patient's geographic location introduces a layer of access complexity that exists entirely independent of whether a given peptide therapy is clinically appropriate for that individual. A provider in a high-access state may be able to evaluate a patient via telehealth, write a prescription, and have a 503B-compounded formulation delivered with relative ease. A provider in a low-access state — or a patient seeking care there — may encounter multiple structural barriers at every step of that same process.

The researchers developed what they describe as a clinician-friendly framework for identifying geographic disparities in access. By making the PAES methodology transparent and reproducible using publicly available data, the study offers a practical tool clinicians may use to contextualize the regulatory environment in which they practice and counsel patients accordingly.

The study also highlights the role of nurse practitioner scope of practice laws as a meaningful driver of access. States that grant NPs full practice authority — allowing them to assess, diagnose, and prescribe independently — may expand the clinical workforce available to manage peptide-based therapies in sexual medicine, particularly in regions with limited physician availability.

It is worth noting that the study's authors acknowledge several limitations. The analysis relied on proxy measures rather than direct prescribing or dispensing data, physician assistant autonomy was not included in the model, and the methodology could not account for within-state variation in socioeconomic factors or urban-rural disparities. Human clinical outcomes data would be needed to assess whether these structural access differences translate into measurable differences in patient health outcomes.

Current Access and Compliance Context

Peptide-based therapies in sexual medicine exist within a regulatory environment that continues to evolve at both the federal and state levels. The FDA's oversight of compounding — particularly through the 503A (traditional compounding) and 503B (outsourcing facility) frameworks — establishes the federal floor for how these agents may be produced and distributed. However, as this study illustrates, federal frameworks do not operate in a uniform state-level landscape.

The presence or absence of FDA-registered 503B outsourcing facilities within a state has practical consequences. These facilities, which operate under heightened quality and safety standards, represent a regulated pathway through which compounded peptide therapies may reach patients. States with fewer or no 503B facilities may create supply chain challenges even when a prescription is legally authorized.

Telehealth regulations — which vary considerably in how they define the patient-provider relationship, what modalities are permitted, and whether prescribing is allowed across state lines — add another layer of complexity. The COVID-19 pandemic prompted many states to temporarily expand telehealth permissions, but those expansions have since been handled inconsistently, contributing to the variability this study quantified.

Clinicians and patients operating in this space are encouraged to remain informed about their specific state's regulatory status and to work with providers and compounding pharmacies who demonstrate rigorous compliance practices.

What Patients Should Know

If you are a patient interested in or currently using peptide-based therapies for sexual health concerns, this research underscores several important points:

• Your state's laws directly affect your options. The research suggests that patients in low-access states may face more barriers to obtaining care through telehealth or accessing compounded formulations — barriers that exist at the system level, not the individual clinical level.
• Not all access is equal. Even if a therapy is technically legal or federally permissible, state-level infrastructure may limit your ability to access it through a qualified, compliant provider and a regulated pharmacy.
• Provider type matters. In states with full NP practice authority, nurse practitioners may be legally positioned to evaluate and manage your care independently. Understanding who is qualified to prescribe in your state is an important first step.
• Ask about compounding sources. Patients are encouraged to ask their providers whether prescriptions will be fulfilled by an FDA-registered 503B outsourcing facility and to understand the safety and quality standards associated with their specific formulations.
• Seek qualified guidance. The complexity of this regulatory environment makes it especially important to work with clinicians who specialize in this area and stay current with evolving state and federal policies.

Conclusion

The 2026 study by Quesada and colleagues offers a timely and methodologically rigorous look at a problem that affects patients and providers across the United States: the significant role that state-level healthcare infrastructure plays in determining who can access peptide-based therapies in sexual medicine. By quantifying these disparities through a reproducible, multidimensional framework, the research contributes a valuable tool for both clinicians and policymakers working to understand — and ultimately reduce — geographic inequities in care.

As the evidence base for peptide therapies in sexual medicine continues to grow, ensuring that patients have access to qualified, compliant providers will remain a critical priority. If you are looking for a knowledgeable clinician in your area, visit peptideassociation.org/find-a-doctor to search our directory of vetted healthcare professionals.

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content reflects findings from a published research study and should not be used as a substitute for consultation with a qualified healthcare professional. Always consult your physician or another licensed healthcare provider regarding any medical condition or treatment options.

Citation (AMA Style): Quesada SG, Ahmed Z, Nakamura HS, et al. Access without approval: state-level determinants of peptide availability in sexual medicine. Sexual Medicine. 2026;(July). doi:10.1093/sexmed/qfag050. PMID: 42394939.